Immunic, Inc. (IMUX) Stock Price & Analysis
Immunic, Inc. (IMUX) fell 6.23% to USD 13.39 as of July 26, 2026 at 20:28 UTC, according to Nexqual real-time market data.
IMUX last closed at USD 14.28; the session ranged USD 13.2–14.38 on volume of 155,707 shares. Market capitalization is $182.39M, with a 52-week range of USD 5.06–15.84 (NCM). Source: Nexqual, July 26, 2026 at 20:28 UTC.
Key Statistics (as of July 26, 2026 at 20:28 UTC)
| Price | USD 13.39 |
|---|---|
| Change | ▼ 6.23% (down) |
| Previous Close | USD 14.28 |
| Open | USD 14.38 |
| Day Range | USD 13.2 – 14.38 |
| 52-Week Range | USD 5.06 – 15.84 |
| Volume | 155,707 shares |
| Market Cap | $182.39M |
| Exchange | NCM |
Technical Analysis (IMUX)
Nexqual's technical model rates IMUX "NEUTRAL" based on 3 bullish and 4 bearish signals across 125 daily candles, as of July 26, 2026 at 20:28 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 39.1 (neutral) |
| vs SMA50 | Below (USD 14.05) |
| MACD | 0.11 (positive) |
Analyst Ratings (IMUX)
Wall Street analysts rate IMUX "Strong Buy" based on 9 analysts, with a mean price target of USD 43.22 (range USD 19–85), per Nexqual as of July 26, 2026 at 20:28 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 43.22 |
| High Target | USD 85 |
| Low Target | USD 19 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (IMUX)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -1.18 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.08 vs est -0.96 ▼ miss |
| 2025-12-31 | USD -0.7 vs est -1.11 ▲ beat |
| 2025-09-30 | USD -1.3 vs est -1.77 ▲ beat |
| 2025-06-30 | USD -2 vs est -1.58 ▼ miss |
Source: Nexqual, July 26, 2026 at 20:28 UTC.
Financials & Fundamentals (IMUX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -142.91% |
| Debt / Equity | 0.28 |
| Current Ratio | 4.92 |
| Total Cash | $186.63M |
| Total Debt | $421,000 |
| Free Cash Flow | $-41.39M |
Source: Nexqual, July 26, 2026 at 20:28 UTC.
Financial Health Score (IMUX)
Nexqual rates Immunic, Inc.'s overall financial health "Mixed" across five dimensions, as of July 26, 2026 at 20:28 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $187M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$81M |
| Efficiency | Critical — ROE -143%, ROA -65.2% |
Ownership (IMUX)
| Insider Ownership | +0.97% |
|---|---|
| Institutional Ownership | +46.94% |
| Shares Outstanding | 13.62M |
| Float | 11.84M |
| Short % of Float | +10.98% |
Source: Nexqual, July 26, 2026 at 20:28 UTC.
Leadership (IMUX)
Immunic, Inc. is led by Jason Tardio (age 48), COO & President, per Nexqual as of July 26, 2026 at 20:28 UTC.
| COO & President | Jason Tardio (age 48) |
|---|---|
| Chief Financial Officer | Glenn Whaley (age 57) |
| Vice President of Investor Relations & Communications | Jessica Breu |
Major Backers & Investors (IMUX)
Notable institutional backers of Immunic, Inc. include Marshall Wace LLP, Aberdeen Group plc, BVF Inc., according to Nexqual as of July 26, 2026 at 20:28 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Marshall Wace LLP | 7% |
| Aberdeen Group plc | 6.05% |
| BVF Inc. | 5.62% |
| Avidity Partners Management, LP | 4.92% |
| abrdn Healthcare Investors | 3.48% |
| Soleus Capital Management, L.P. | 3.3% |
| Laurion Capital Management, LP | 2.85% |
| Millennium Management | 2.77% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.51% |
Source: Nexqual, July 26, 2026 at 20:28 UTC.
From Immunic, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany.
- Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
- The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IFRX | InflaRx N.V. | USD 1.74 | ▼ 3.33% |
| CTMX | CytomX Therapeutics, Inc. | USD 3.24 | ▼ 2.7% |
| NKTX | Nkarta, Inc. | USD 2.27 | ▼ 5.81% |
| KALA | KALA BIO, Inc. | USD 0.63 | ▼ 13.95% |
| GOSS | Gossamer Bio, Inc. | USD 0.14 | ▼ 6.21% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 20:28 UTC. This page is informational and not investment advice.